An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A 73-year-old woman is thinking about trying a drug in the GLP class (the family that includes medicines like Ozempic and Wegovy) because she wants help with binge eating and to improve metabolic health. She’s very small and worried about losing too much weight. The note you gave is basically someone asking whether a GLP “secretagogue” (a drug that increases a hormone called growth hormone) or a micro-dose approach exists that would help binges and metabolism without causing dangerous weight loss. The drug class being discussed—GLP receptor agonists—are synthetic versions of a natural gut hormone that signals fullness and slows stomach emptying. People use them for type 2 diabetes and for weight loss because they reduce appetite and calorie intake. They are not the same as growth hormone (GH) or “secretagogues” (agents that trigger the body to release GH); GLP drugs act on different receptors tied to appetite and blood sugar control. So the idea of a GLP drug that acts as a GH secretagogue would be mixing two different concepts. What the available research shows is mostly clear about GLP drugs: in clinical trials with thousands of people, they reduce appetite, lead to weight loss, and improve blood sugar and some metabolic markers. Those trials mainly involved adults with overweight or obesity, not very frail, very small elderly people. There isn’t good evidence that low micro-doses preserve metabolic benefits while avoiding weight loss in someone who is already very small. As for GH secretagogues in elderly people, studies are limited and mixed; some small trials showed modest increases in growth-hormone levels or lean mass, but benefits for strength, function, or long-term health are uncertain and side effects can be meaningful. In short, the specific combo you’re asking about—micro-dosing a GLP drug to get metabolic/binge control without weight loss, or replacing that with a GH secretagogue—doesn’t have solid, large-scale evidence to support it. Why this matters: older adults who are small or frail have different risks and goals than younger people trying to lose weight. For this woman, losing more weight could be harmful—reducing muscle, lowering energy and resilience, and increasing fracture or illness risk. On the other hand, if binge eating or poor metabolic health are causing problems, treating those could improve quality of life. Decisions need to be individualized: a doctor should look at her current weight, muscle mass, nutritional status, blood sugar, medications, and goals before starting any GLP drug or experimental secretagogue approach. Caveats and risks: GLP receptor drugs commonly cause nausea, reduced appetite, and weight loss—effects that may be undesirable or unsafe in a very small elderly person. They can also cause constipation, low blood sugar when combined with other diabetes meds, and rare serious problems like pancreatitis. Growth-hormone secretagogues have their own risks and are not approved for broad use to improve aging; they can affect blood sugar, fluid balance, and potentially cancer risk in theory, and many products marketed as “secretagogues” are unregulated. Regulatory status matters: GLP drugs are prescription medicines approved for specific conditions; off-label dosing or use without medical supervision is risky. Always discuss options with a clinician who knows geriatric care and can monitor weight, muscle strength, nutrition, and labs. Bottom line: GLP drugs can help binges and metabolism but usually cause weight loss; for a very small older person this could be harmful, and there’s no proven micro-dose workaround or safe GH substitute ready for routine use. Get a specialist’s assessment before trying anything.
Source: r/Peptides